At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 76 enrolled
Drug / intervention
Eribulin mesylate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2, Multicenter, Open-Label, Dose-Escalation and Confirmation Study of Eribulin in Combination With Capecitabine
In Brief
A Phase 2 clinical trial evaluating Eribulin mesylate and Capecitabine for Metastatic Breast Cancer. Completed, enrolled 76 participants across 10 sites in 3 countries.
Detailed Summary
This is a Phase 1b/2, multi-center, open-label, dose escalation (in 2 different dosing schedules \[1 and 2\]) and dose-confirmation study of eribulin administered in combination with capecitabine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesBulgaria, Russia, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedMar 2011
Primary CompletionJul 2014
Study CompletionOct 2015
TodayJul 2026
First PostedMar 25, 2011
Enrollment StartJan 26, 2010
Primary CompletionJul 28, 2014
Study CompletionOct 13, 2015
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 15.3 years ago
Interventions
Eribulin mesylatedrug
Intravenous (IV) bolus or infusion.
Capecitabinedrug
Oral film-coated tablets.